Products with Anti-hyperlipidemic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5246 | Oleuropein |
| Oleuropein exhibits anti-ischemic, antioxidative, hypolipidemic, in vitro antimycoplasmal , anti-inflammatory, and anti-cancer effects., it also may be helpful in the prevention of diabetic complications associated with oxidative stress. Oleuropein prevents oxidative myocardial injury induced by ischemia and reperfusion, and reduces viremia in duck hepatitis B virus (DHBV)-infected ducks. Oleuropein reduces TLR and MAPK signaling. | |
| BCN5249 | Cajanin |
| 1. Cajanin has strong mitogenic as well as differentiation-promoting effects on osteoblasts that involved subsequent activation of MEK-Erk and Akt pathways. 2. Cajanin has potential hypolipidemic effects,possibly via up-regulating the ABCA1 protein expression,subsequently resulting in increased macrophage cholesterol efflux and RCT. 3. Cajanin can significantly improve basal glucose uptake in HepG2 cells, its improving effect is concentration dependent, it exhibits effects stronger than that of rosiglitazone, which has been used as an antidiabetic drug. | |
| BCN5266 | Alpinumisoflavone |
| 1. Alpinumisoflavone has atheroprotective effects, may result from their ability to upregulate mechanisms promoting HDL-cholesterol and bile acid formation. 2. Alpinumisoflavone is endowed with estrogenic properties accounting, at least in part, for E. lysistemon effects. 3. Alpinumisoflavone induces cell death, may be via repressing both the ERK/MAPK and NF-κB pathways. 4. Alpinumisoflavone, abyssione-V 4'-O-methyl ether, 6,8-diprenylgenistein, and burttinone are active against both Gram-negative and Gram-positive bacteria, the minimum inhibitory concentration values obtained (MIC) ranged from 3.9 ug/mL to 125 ug/mL. | |
| BCN5319 | Jatrorrhizine |
| Jatrorrhizine has neuroprotective, antioxidative, anti-inflammatory, antihypercholesterolemic, and anti-hyperglycemia effects.Jatrorrhizine is expected to be developed as a new gastric prokinetic drug, it is metabolized by human CYP1A2 and multiple UGT1A isoforms. It has inhibitory activities against the expression of inducible NO syntase (iNOS) and cyclooxygenase-2 (COX-2), and can improve the utilization and excretion of cholesterol by up-regulating the mRNA and protein expression of LDLR and CYP7A1. | |
| BCN5344 | Buddlejasaponin IV |
| 1. Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation, are responsible for the anti-inflammatory effects of buddlejasaponin IV. 2. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat. 3. Buddlejasaponin IV exerts antiinflammatory and cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes. 4. Buddlejasaponin IV may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. | |
